Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2001

Study Completion Date

May 31, 2006

Conditions
Ovarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

gefitinib

Trial Locations (53)

1450

Australia New Zealand Gynaecological Oncology Trials Group, Camperdown

10021

Memorial Sloan-Kettering Cancer Center, New York

11030

Schneider Children's Hospital at North Shore, Manhasset

11203

State University of New York Health Science Center at Brooklyn, Brooklyn

12208

Cancer Center of Albany Medical Center, Albany

19001

Abington Memorial Hospital, Abington

19111

Fox Chase Cancer Center, Philadelphia

20892

Medical Oncology Clinical Research Unit, Bethesda

22908

Cancer Center at the University of Virginia, Charlottesville

27710

Duke Comprehensive Cancer Center, Durham

37203

Brookview Research, Inc., Nashville

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

55455

University of Minnesota Cancer Center, Minneapolis

55905

Mayo Clinic Cancer Center, Rochester

60612

Rush-Presbyterian-St. Luke's Medical Center, Chicago

63110

Washington University School of Medicine, St Louis

65203

Ellis Fischel Cancer Center - Columbia, Columbia

73190

University of Oklahoma College of Medicine, Oklahoma City

80010

University of Colorado Cancer Center, Denver

92868

Chao Family Comprehensive Cancer Center, Orange

95032

Community Hospital of Los Gatos, Los Gatos

98405

Tacoma General Hospital, Tacoma

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

20307-5000

Walter Reed Army Medical Center, Washington D.C.

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

60637-1470

University of Chicago Cancer Research Center, Chicago

46202-5289

Indiana University Cancer Center, Indianapolis

52242-1009

Holden Comprehensive Cancer Center at The University of Iowa, Iowa City

40536-0084

Albert B. Chandler Medical Center, University of Kentucky, Lexington

02111

Tufts University School of Medicine, Boston

01655

University of Massachusetts Memorial Medical Center, Worcester

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

39216-4505

University of Mississippi Medical Center, Jackson

39534-2576

Keesler Medical Center - Keesler AFB, Keesler Air Force Base

08103

Cooper Hospital/University Medical Center, Camden

14263-0001

Roswell Park Cancer Institute, Buffalo

11790-7775

State University of New York Health Sciences Center - Stony Brook, Stony Brook

27599-7295

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

27157-1082

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

45267-0502

Barrett Cancer Center, The University Hospital, Cincinnati

44106-5065

Ireland Cancer Center, Cleveland

43210-1240

Arthur G. James Cancer Hospital - Ohio State University, Columbus

17033-0850

Milton S. Hershey Medical Center, Hershey

19104-4283

University of Pennsylvania Cancer Center, Philadelphia

19107-5541

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia

29425-0721

Medical University of South Carolina, Charleston

75235-9154

Simmons Cancer Center - Dallas, Dallas

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

05401

Fletcher Allen Health Care - Medical Center Campus, Burlington

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

T2N 4N2

Tom Baker Cancer Center - Calgary, Calgary

B15 2TT

University of Birmingham, Birmingham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00023699 - Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter